Back to Search
Start Over
Oral vinorelbine in the treatment of non-small-cell lung cancer
- Source :
- Expert Opinion on Pharmacotherapy. 15:1585-1599
- Publication Year :
- 2014
- Publisher :
- Informa Healthcare, 2014.
-
Abstract
- Originally formulated as an intravenous (i.v.) agent, vinorelbine is also currently available as an oral chemotherapeutic agent. Oral vinorelbine has demonstrated significant activity in different settings for NSCLC, including adjuvant treatment for resected disease, concurrent chemoradiation for locally advanced NSCLC and palliative chemotherapy for recurrent/metastatic NSCLC, as part of combination schedules or as a single-agent treatment.The authors explored the available data describing the use of oral vinorelbine in NSCLC. PubMed articles and abstracts presented at international conferences were analysed, and relevant trials were reported and discussed. Specific settings, including the treatment of elderly and unfit patients and metronomic schedules including oral vinorelbine, were evaluated. Available pharmacoeconomic data were also assessed.Oral vinorelbine is an appealing agent, particularly as part of combination regimens containing platinum derivatives, although it can have a role as a single-agent treatment as well. Its safety profile is generally favourable and its route of administration is generally preferred by patients receiving chemotherapy. Compared to i.v. vinorelbine and other antineoplastic agents, oral vinorelbine has been reported to be advantageous in terms of cost savings.
- Subjects :
- Oncology
medicine.medical_specialty
Lung Neoplasms
medicine.drug_class
medicine.medical_treatment
Locally advanced
Administration, Oral
Antineoplastic Agents
Vinblastine
Vinorelbine
Vinca alkaloid
Carcinoma, Non-Small-Cell Lung
Internal medicine
medicine
Humans
Pharmacology (medical)
Lung cancer
Randomized Controlled Trials as Topic
Pharmacology
Chemotherapy
business.industry
General Medicine
Concurrent chemoradiation
medicine.disease
Treatment Outcome
Chemotherapy, Adjuvant
Non small cell
business
Adjuvant
medicine.drug
Subjects
Details
- ISSN :
- 17447666 and 14656566
- Volume :
- 15
- Database :
- OpenAIRE
- Journal :
- Expert Opinion on Pharmacotherapy
- Accession number :
- edsair.doi.dedup.....b60ca30a4728d759c414120471743b52